Orion Infusion Limited Share Price

Equities

ORIONINFU

BD0472ORINF6

Pharmaceuticals

End-of-day quote Dhaka S.E. 23:00:00 24/04/2024 BST 5-day change 1st Jan Change
611.7 BDT +2.51% Intraday chart for Orion Infusion Limited +22.93% +69.31%

Financials

Sales 2022 830M 7.54M 604M Sales 2023 810M 7.37M 590M Capitalization 6.85B 62.3M 4.99B
Net income 2022 42M 382K 30.57M Net income 2023 41M 373K 29.84M EV / Sales 2022 2.49 x
Net Debt 2022 290M 2.64M 211M Net Debt 2023 320M 2.91M 233M EV / Sales 2023 8.85 x
P/E ratio 2022
41.5 x
P/E ratio 2023
164 x
Employees 764
Yield 2022
2.29%
Yield 2023
0.3%
Free-Float 59.39%
More Fundamentals * Assessed data
Dynamic Chart
Orion Infusion Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Orion Infusion Limited Recommends Cash Dividend for the Year Ended June 30, 2023 CI
Orion Infusion Limited Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Orion Infusion Limited Announces Executive Changes CI
Orion Infusion Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023 CI
Orion Infusion Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022 CI
Orion Infusion Limited Reports Earnings Results for the First Quarter Ended September 30, 2022 CI
Orion Infusion Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022 CI
Orion Infusion Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021 CI
Orion Infusion Limited Reports Earnings Results for the First Quarter Ended September 30, 2021 CI
Orion Infusion Limited Reports Earnings Results for the Third Quarter Ended March 31, 2021 CI
Orion Infusion Limited Recommends Cash Dividend for Year Ended on June 30, 2020 CI
Orion Infusion Limited Reports Earnings Results for the First Quarter Ended September 30, 2020 CI
Orion Infusion Limited Reports Earnings Results for the Third Quarter Ended March 31, 2020 CI
Orion Infusion Limited Reports Earnings Results for the Second Quarter Ended December 31, 2019 CI
More news
1 day+2.51%
1 week+22.93%
Current month+18.68%
1 month+20.32%
3 months+26.49%
6 months+85.48%
Current year+69.31%
More quotes
1 week
485.90
Extreme 485.9
620.00
1 month
478.00
Extreme 478
620.00
Current year
345.00
Extreme 345
726.90
1 year
284.20
Extreme 284.2
726.90
3 years
65.00
Extreme 65
1 000.00
5 years
46.00
Extreme 46
1 000.00
10 years
34.30
Extreme 34.3
1 000.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 42 31/12/99
Director of Finance/CFO - 07/11/20
Chief Administrative Officer - -
Members of the board TitleAgeSince
Founder 69 04/05/83
Founder 68 04/05/83
Chief Executive Officer 42 31/12/99
More insiders
Date Price Change Volume
25/04/24 611.7 +2.51% 526,437
24/04/24 596.7 +5.02% 399,997
23/04/24 568.2 +7.49% 437,208
22/04/24 528.6 +8.74% 543,944
21/04/24 486.1 -2.31% 174,055

End-of-day quote Dhaka S.E., April 24, 2024

More quotes
Orion Infusion Limited is a Bangladesh-based large volume parenteral (LVP) manufacturing company. The Company is a provider of quality medicines and health care services through approximately 28 brands and 42 presentations of various formulations. The Company is engaged in manufacturing and marketing of Intravenous (I.V.) fluid, lifesaving intravenous medicine and intravascular saline, which include fluid and nutrient, fluid and electrolyte, fat emulsion for I.V. use, fluid, nutrient and electrolyte, plasma substitute, antiulcerant, osmotic diuretic and amino acid solutions. The Company has the manufacturing facilities for the production of I.V. Rehydration Solutions, Electrolyte Solutions, and Solution for Acidosis, Ranitidine I.V. infusion, Anti-Microbial products viz. Ciprofloxacin I.V., Metronidazole I.V. and others. The Company's production plant is situated at Maikuli, P.S. Rupganj, and District- Naraynganj, Bangladesh.
More about the company
  1. Stock Market
  2. Equities
  3. ORIONINFU Stock